Trial reportSurgical endoscopy2026
Comparison of apixaban and warfarin in preventing portal vein system thrombosis after laparoscopic splenectomy for cirrhotic patients with secondary hypersplenism: a randomized controlled trial.
Trial report in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPortal vein system thrombosis (PVST) is a critical complication after laparoscopic splenectomy (LS). For its treatment, warfarin is widely used in clinical practice, but there are obvious limitations. Apixaban, a novel oral anticoagulant, may offer an alternative treatment option. The objective of this study was to compare the safety and efficacy of apixaban versus warfarin in preventing PVST after LS in cirrhotic patients with secondary hypersplenism.
methodsThis study was designed as a randomized controlled trial conducted at the Hepatobiliary and Pancreatic Center of our hospital from September 2020 to December 2023. A total of 80 cirrhotic patients who underwent LS were randomly assigned to receive either apixaban or warfarin for a period of 6 months. Generalized estimating equations (GEE) were employed to analyze the impact of different anticoagulant regimens on the incidence of PVST after LS in cirrhotic patients with secondary hypersplenism, as well as to assess the temporal risk of thrombosis.
resultsNo adverse events were observed during follow-up. According to GEE, excluding the effect of time, the overall incidence of PVST in the warfarin group was significantly different from that in the apixaban group (31.3% vs. 13.8%; W = 8.217, P = 0.004), and further analysis revealed that the risk of PVST in the warfarin group was significantly higher than in the apixaban group (odds ratio: 3.118, 95% confidence interval: 1.433 to 6.784; P = 0.004). Furthermore, the overall incidence of PVST varied significantly across different time points, demonstrating a consistently decreasing trend over time (W = 21.101, P < 0.001).
conclusionIn the prevention of PVST after LS in cirrhotic patients with secondary hypersplenism, apixaban can be considered as the preferred anticoagulation strategy due to its superior efficacy and similar safety comparable to warfarin.
Indexed as
Identifiers
41131381What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.